a Department of Pharmacology , Al-Ameen College of Pharmacy , Bangalore , India.
b The Musculoskeletal Genetics Laboratory, Faculty of Medicine in the Galilee , Bar-Ilan University , Safed , Israel.
J Biomater Sci Polym Ed. 2018 Jan;29(1):74-91. doi: 10.1080/09205063.2017.1400145. Epub 2017 Nov 8.
The aim of this study was to develop a chitosan-based risedronate/zinc-hydroxyapatite intrapocket dental film (CRZHDF) for applications in the treatment of alveolar bone loss in an animal model of periodontitis. The physical characteristics (folding endurance, pH, mucoadhesive strength, risedronate content and release) of CRZHDF, exhibited results within the limit. X-ray diffraction analysis indicates reduced or disappeared crystallinity of risedronate and zinc-hydroxyapatite in presence of chitosan. Further, FTIR studies revealed stability of CRZHDF and compatibility between risedronate, zinc-hydroxyapatite and chitosan. Periodontitis was induced by Porphyromonas gingivalis-lipopolysaccharide injections around the mandibular first molar. We divided rats into 5 groups (12 rats/group): healthy, untreated periodontitis; periodontitis plus CRZHDF-A, periodontitis plus CRZHDF-B, and periodontitis plus chitosan film. After four weeks, blood samples and mandibles were obtained for biochemical, radiographic and histological analysis. Bone specific alkaline phosphatise activity and tartrate resistant acid phosphatase 5b was statistically lower in CRZHDF-A and CRZHDF-B groups as compared to the untreated periodontitis group (p < 0.0001). The expression of osteocalcin was statistically higher in CRZHDF-A and CRZHDF-B groups as compared to the untreated periodontitis group (p < 0.0001). Alveolar bone was intact in the healthy group. Local administration of CRZHDF resulted in significant improvements in the mesial and distal periodontal bone support (MPBS and DPBS, respectively) proportions (%), bone mineral density, and also reversed alveolar bone resorption when compared to the untreated periodontitis group (p < 0.001). The study reported here reveals that novel CRZHDF treatment effectively reduced alveolar bone destruction and contributes to periodontal healing in a rat model of experimental periodontitis.
本研究旨在开发一种壳聚糖载利塞膦酸钠/锌-羟基磷灰石口袋内牙膜（CRZHDF），用于治疗牙周炎动物模型中的牙槽骨丧失。CRZHDF 的物理特性（耐折性、pH 值、黏膜黏附强度、利塞膦酸钠含量和释放）均在限度内。X 射线衍射分析表明壳聚糖存在时利塞膦酸钠和锌-羟基磷灰石的结晶度降低或消失。此外，傅里叶变换红外光谱研究表明 CRZHDF 稳定，利塞膦酸钠、锌-羟基磷灰石和壳聚糖之间相容。通过在下颌第一磨牙周围注射牙龈卟啉单胞菌-脂多糖诱导牙周炎。我们将大鼠分为 5 组（每组 12 只）：健康对照组、未治疗牙周炎组、牙周炎加 CRZHDF-A 组、牙周炎加 CRZHDF-B 组和牙周炎加壳聚糖膜组。四周后，采集血样和下颌骨进行生化、放射学和组织学分析。与未治疗牙周炎组相比，CRZHDF-A 和 CRZHDF-B 组的骨特异性碱性磷酸酶活性和抗酒石酸酸性磷酸酶 5b 统计学上较低（p<0.0001）。CRZHDF-A 和 CRZHDF-B 组的骨钙素表达明显高于未治疗牙周炎组（p<0.0001）。健康组牙槽骨完整。与未治疗牙周炎组相比，局部给予 CRZHDF 可显著改善近中和远中牙周骨支持（MPBS 和 DPBS）比例（%）、骨密度，并逆转牙槽骨吸收（p<0.001）。本研究报告的新型 CRZHDF 治疗有效减少了牙槽骨破坏，并有助于实验性牙周炎大鼠模型中的牙周愈合。
